A detailed history of Guggenheim Capital LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 55,811 shares of ACAD stock, worth $958,274. This represents 0.01% of its overall portfolio holdings.

Number of Shares
55,811
Previous 56,917 1.94%
Holding current value
$958,274
Previous $924,000 7.14%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.14 - $19.14 $16,744 - $21,168
-1,106 Reduced 1.94%
55,811 $858,000
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $105,863 - $133,379
7,241 Added 14.58%
56,917 $924,000
Q1 2024

May 14, 2024

BUY
$17.79 - $30.86 $26,987 - $46,814
1,517 Added 3.15%
49,676 $918,000
Q4 2023

Feb 14, 2024

BUY
$20.78 - $31.77 $65,623 - $100,329
3,158 Added 7.02%
48,159 $1.51 Million
Q3 2023

Nov 14, 2023

SELL
$20.84 - $33.47 $59,081 - $94,887
-2,835 Reduced 5.93%
45,001 $937,000
Q2 2023

Aug 11, 2023

SELL
$17.8 - $25.65 $55,126 - $79,438
-3,097 Reduced 6.08%
47,836 $1.15 Million
Q1 2023

May 10, 2023

BUY
$16.32 - $20.92 $831,226 - $1.07 Million
50,933 New
50,933 $958,000
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $139,896 - $292,696
-10,753 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$20.94 - $27.5 $32,101 - $42,157
1,533 Added 16.63%
10,753 $261,000
Q4 2021

Feb 14, 2022

SELL
$16.79 - $27.09 $1.43 Million - $2.3 Million
-85,059 Reduced 90.22%
9,220 $216,000
Q3 2021

Nov 15, 2021

BUY
$15.78 - $24.77 $231,429 - $363,276
14,666 Added 18.42%
94,279 $1.57 Million
Q2 2021

Aug 13, 2021

BUY
$19.4 - $27.42 $26,771 - $37,839
1,380 Added 1.76%
79,613 $1.94 Million
Q1 2021

May 13, 2021

BUY
$25.02 - $54.99 $575,359 - $1.26 Million
22,996 Added 41.63%
78,233 $2.02 Million
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $944,289 - $1.31 Million
-23,009 Reduced 29.41%
55,237 $2.95 Million
Q3 2020

Nov 13, 2020

SELL
$36.42 - $57.0 $389,876 - $610,185
-10,705 Reduced 12.03%
78,246 $3.23 Million
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $293,743 - $394,525
7,482 Added 9.18%
88,951 $4.31 Million
Q1 2020

Jun 02, 2020

SELL
$31.65 - $46.87 $566,598 - $839,066
-17,902 Reduced 18.02%
81,469 $3.44 Million
Q4 2019

Feb 14, 2020

BUY
$36.21 - $51.4 $558,249 - $792,433
15,417 Added 18.36%
99,371 $4.25 Million
Q3 2019

Nov 14, 2019

SELL
$22.22 - $44.01 $670,044 - $1.33 Million
-30,155 Reduced 26.43%
83,954 $3.02 Million
Q2 2019

Aug 14, 2019

SELL
$23.32 - $28.12 $356,749 - $430,179
-15,298 Reduced 11.82%
114,109 $3.05 Million
Q1 2019

May 15, 2019

SELL
$16.17 - $27.38 $529,761 - $897,023
-32,762 Reduced 20.2%
129,407 $3.48 Million
Q4 2018

Feb 14, 2019

SELL
$14.32 - $22.92 $53,914 - $86,293
-3,765 Reduced 2.27%
162,169 $2.62 Million
Q3 2018

Nov 14, 2018

SELL
$13.03 - $21.81 $95,952 - $160,608
-7,364 Reduced 4.25%
165,934 $3.45 Million
Q2 2018

Aug 14, 2018

BUY
$15.07 - $22.34 $282,547 - $418,852
18,749 Added 12.13%
173,298 $2.65 Million
Q1 2018

May 15, 2018

BUY
$22.47 - $32.33 $189,579 - $272,768
8,437 Added 5.77%
154,549 $3.47 Million
Q4 2017

Feb 14, 2018

SELL
$26.84 - $39.14 $433,492 - $632,150
-16,151 Reduced 9.95%
146,112 $4.4 Million
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $4.79 Million - $6.23 Million
162,263
162,263 $6.11 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.78B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.